SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 202.50-2.7%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (20912)5/16/1998 1:18:00 AM
From: bob zagorin  Read Replies (2) of 32384
 
here's the detail from Lehman Bros. are the results as they are because they're dealingwith advanced HIV patients?

Ligand (LGND, 14 1/4, 1-Buy)
Ligand had 4 abstracts accepted by ASCO. The first is preclinical data
showing that receptor selective retinoids can inhibit tumor cell lines. The
second and third are phase I/II dose ranging trials using oral LGD1550 (May
18- 1:00PM-5:00PM Poster session) in patients with advanced cancer to evaluate
pharmacokinetics, safety, clinical tolerance and attempt to determine the
maximally tolerated dose. The fourth abstract is a phase II trial using oral
LGD1057 in AIDS related Kaposi sarcoma. An interim analysis of 66 patients
was completed. 38 patients received at least 16 weeks of drug and were
included in the analysis. Partial responses were seen in 14 patients (37%),
stable disease in 15 (39%) and progressive disease in 4 (11%). 11 patients
withdrew from the study due to adverse events, which included grade 3 or 4
elevations of triglycerides (5 pts.), headaches (8 pts.) and skin problems.
Cholesterol and triglyceride levels rose significantly from a mean baseline
cholesterol level of 187 to 277 and a mean baseline triglyceride level from
240 to 788.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News